NRXP - NASDAQ

NRx Pharmaceuticals, Inc.

NRXP·NASDAQ

$4.05

-12%

HealthcareBiotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$70.01M

EPS-1.3400

P/E Ratio-3.02

Earnings Date08/17/2026

nrxp

Other Non-Cash Items

Last Annual Value

12.73M

3-Year CAGR

70%

5-Year CAGR

-20%

10-Year CAGR

60%

Adjust for Inflation

NRx Pharmaceuticals, Inc. Competitors Analysis of Other Non-Cash Items

NRXP · NASDAQ

Company	Other Non-Cash Items	CAGR 3Y	CAGR 5Y	CAGR 10Y
NRx Pharmaceuticals, Inc. NASDAQ:NRXP	12.73M	63.0%	-24.7%	N/A
Equillium, Inc. NASDAQ:EQ	-469.00K	N/A	N/A	N/A
Coeptis Therapeutics, Inc. NASDAQ:COEP	2.34M	-40.0%	-11.3%	N/A
Cue Biopharma, Inc. NASDAQ:CUE	2.51M	203.2%	N/A	43.9%
Aligos Therapeutics, Inc. NASDAQ:ALGS	-60.50M	N/A	N/A	N/A
MediciNova, Inc. NASDAQ:MNOV	878.83K	43.5%	32.3%	39.2%
OS Therapies Incorporated NYSE:OSTX	1.46M	-19.2%	-9.8%	N/A
Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV	1.03M	-1.2%	-6.0%	N/A
Relmada Therapeutics, Inc. NASDAQ:RLMD	-41.84M	N/A	N/A	N/A
Outlook Therapeutics, Inc. NASDAQ:OTLK	1580.49B	6434.3%	2053.1%	541.1%
Werewolf Therapeutics, Inc. NASDAQ:HOWL	856.00K	-0.8%	10.5%	N/A

NRx Pharmaceuticals, Inc. Fair Value Envelope

NRXP · NASDAQ

Our analysis suggests that NRXP has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.05, this represents a potential HIDDEN relative to our calculated worth for NRx Pharmaceuticals, Inc..

HIDDEN

Intrinsic Value

Current Price: $4.05

Related Guides

Blog Categories

Continue your NRXP research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.